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The	ileal	mucosa	of	Crohn	disease	(CD)	patients	is	abnormally	colonized	by	adherent-invasive	E. coli	(AIEC)	
that	are	able	to	adhere	to	and	invade	intestinal	epithelial	cells.	Here,	we	show	that	CD-associated	AIEC	strains	
adhere	to	the	brush	border	of	primary	ileal	enterocytes	isolated	from	CD	patients	but	not	controls	without	
inflammatory	bowel	disease.	AIEC	adhesion	is	dependent	on	type	1	pili	expression	on	the	bacterial	surface	and	
on	carcinoembryonic	antigen–related	cell	adhesion	molecule	6	(CEACAM6)	expression	on	the	apical	surface	
of	ileal	epithelial	cells.	We	report	also	that	CEACAM6	acts	as	a	receptor	for	AIEC	adhesion	and	is	abnormally	
expressed	by	ileal	epithelial	cells	in	CD	patients.	In	addition,	our	in	vitro	studies	show	that	there	is	increased	
CEACAM6	expression	in	cultured	intestinal	epithelial	cells	after	IFN-γ	or	TNF-α	stimulation	and	after	infec-
tion	with	AIEC	bacteria,	indicating	that	AIEC	can	promote	its	own	colonization	in	CD	patients.
Introduction
Idiopathic inflammatory bowel diseases (IBDs), which include 
Crohn disease (CD) and ulcerative colitis (UC), are chronic disorders 
of the gastrointestinal tract of unknown etiology with a combined 
prevalence of about 150–200 cases per 100,000 in Western countries 
(1). The pathogenesis of CD is complex and consists of 3 interacting 
elements: genetic susceptibility factors, such as NOD2/CARD15; 
priming by the enteric microflora; and immune-mediated tissue 
injury (2–6). E. coli is the predominant aerobic Gram-negative spe-
cies of the normal intestinal flora, where it plays an important 
role by promoting the stability of the luminal microbial flora and 
maintaining normal intestinal homeostasis. Modifications of 
luminal bacteria concentrations have been observed in CD patients. 
Indeed, the neoterminal ileum of CD patients is heavily colonized 
by a colonic-like bacterial flora, with E. coli predominating (7, 8). 
In a study to assess the predominance of E. coli strains associated 
with the ileal mucosa of CD patients, E. coli was recovered from 
65% of chronic lesions (resected ileum) and from 100% of the biop-
sies of early lesions (postoperative endoscopic recurrence). E. coli 
were abnormally predominant (between 50% and 100% of the total 
number of aerobes and anaerobes) in early and chronic ileal lesions 
of CD patients (9). The presence of high concentrations of bacteria 
forming a biofilm on the surface of the gut mucosa was reported in 
patients with CD and UC (10). We observed that, in a given patient, 
healthy and ulcerated mucosa were colonized by E. coli strains hav-
ing the same ribotype profile, which indicates uniform coloniza-
tion regardless of the inflammatory state of the mucosa (11). Thus, 
patients with CD appear to have defective handling of luminal bac-
teria and an increased number of mucosal bacteria (10).
The neoterminal ileum of CD patients is heavily colonized by 
E. coli strains able to adhere to and to invade cultured intestinal epi-
thelial cells (9, 12). These E. coli strains, termed adherent-invasive 
E. coli (AIEC), are also able to survive extensively within macrophages 
and to induce the secretion of high amounts of TNF-α (13). Among 
the virulence factors harbored by AIEC strains, type 1 pili mediate 
adherence to intestinal epithelial cells and also play an essential part 
in the invasive ability of AIEC reference strain LF82 by inducing mem-
brane extensions, which surround the bacteria at the sites of contact 
between the entering bacteria and the epithelial cells (14). In neo-
terminal ileal specimens, AIEC strains were found in 36.4% of early 
CD lesions and also in 22.2% of uninvolved mucosa of CD patients 
(15). However, AIEC strains do not represent a specific pathogen 
exclusively found in CD because their presence was also observed in 
6.2% of ileal and 1.9% of colonic control specimens. The high preva-
lence of AIEC strains associated with the ileal mucosa observed in 
CD patients suggests an abnormal expression and/or tissue tropism 
of a specific host receptor recognized by bacterial lectin-like surface 
adhesins in a genetically predisposed host gut segment. Thus, we 
investigated the ability of CD-associated AIEC strains to colonize the 
ileal mucosa by analyzing their adhesion to isolated ileal enterocytes, 
the bacterial adherence factor involved, and the presence of an intes-
tinal epithelial cell receptor responsible for bacterial adhesion.
Results
AIEC strain LF82 adheres to the brush border of primary ileal enterocytes 
from CD patients. Adhesion of CD-associated AIEC reference strain 
LF82 was investigated using primary ileal epithelial cells isolated 
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from 15 CD patients and 9 controls without IBD. LF82 bacteria 
adhered preferentially to the brush border of ileal enterocytes iso-
lated from CD patients (Figure 1A). Brush border adhesion indi-
ces of E. coli LF82, corresponding to the mean number of bacteria 
adherent to the brush border, ranged from 0.542 to 1.999 with 
enterocytes isolated from CD patients and from 0.096 to 0.511 
with enterocytes from controls (Figure 1B). The ability of AIEC 
strain LF82 to adhere was therefore significantly higher with 
enterocytes isolated from CD patients than with those from con-
trols (P = 0.0013). This supports the view that, in CD patients, a 
receptor involved in the adhesion of AIEC strain LF82 is expressed 
on the brush border of ileal enterocytes.
Adhesion of AIEC strains involves mannose residues and type 1 pili 
expression. As type 1 pili–mediated adherence to cultured intesti-
nal epithelial cells plays an essential part in the virulence of AIEC 
strain LF82 (14), we investigated their involvement in the adhe-
sion of LF82 bacteria to primary ileal enterocytes. In contrast 
to wild-type LF82, the LF82 type 1 pili–negative mutant 52D11 
(fimA::Tn5phoA) (Figure 2A) and the LF82 FimH adhesin–negative 
mutant ZG2 (fimH::Tn5phoA) (data not shown) did not adhere to 
the brush border of enterocytes isolated from CD patients. The 
adhesion levels of the wild-type strain LF82 on the brush border 
of primary enterocytes isolated from healthy donors were very 
low, and therefore we did not observe any significant decrease 
in the adhesion ability of the type 1 pili–negative mutants com-
pared with that of the wild-type strain (Figure 2A). In addition, 
adhesion of LF82 strain to the brush border of CD enterocytes 
was blocked in the presence of 2% d-mannose (Figure 2B). How-
ever, when primary enterocytes isolated from healthy donors were 
used, d-mannose induced no significant decreases in the adhesion 
levels of LF82 bacteria on the brush border, mostly due to the 
very low adhesion levels observed even in the absence of d-man-
nose (Figure 2B). This suggests that the interaction between AIEC 
LF82 type 1 pili and CD ileal enterocytes occurs via mannose resi-
dues expressed on the apical side of CD enterocytes. Adhesion 
experiments using primary ileal epithelial cells isolated from CD 
patients was extended to 4 other CD-associated AIEC strains 
(LF31, LF71, LF73, and LF100). As shown in Table 1, all AIEC 
strains tested, like strain LF82, were able to adhere to the brush 
border of primary enterocytes isolated from CD patients. Their 
ability to adhere was blocked using 2% d-mannose (Table 1), and 
corresponding type 1 pili–negative mutants were unable to adhere 
to the brush border (Table 1). These results demonstrate that the 
ability of bacteria to adhere via a type 1 pili–mediated adherence 
pathway to the brush border of primary ileal enterocytes from CD 
patients is not restricted to the AIEC reference strain LF82 but is 
a characteristic of CD-associated AIEC strains.
AIEC strains expressed type 1 pili variants. The adhesion level 
of AIEC LF82 expressing such type 1 pili variant was substantial-
ly higher than that of a nonpathogenic E. coli K-12 in which an 
overexpression of regular type 1 pili was induced (Figure 2C). This 
was not due to differences in type 1 pili expression, since Western 
blot analysis revealed similar amounts of type 1 pili expression in 
these 2 strains (Figure 2C). To confirm the greater ability of LF82 
type 1 pili variant compared with the K-12 type 1 pili to adhere, we 
engineered an AIEC LF82 strain expressing E. coli K-12 type 1 pili. 
AIEC strain LF82 expressing K-12 type 1 pili was able to adhere, 
but to a lesser extent than AIEC strain LF82 expressing type 1 
pili variant (Figure 2C). To further analyze the adhesion of AIEC 
strain LF82 to the brush border of ileal enterocytes involving type 
1 pili expression, enterocytes from CD patients or controls were 
incubated with FITC-labeled concanavalin A (ConA), which binds 
to mannose. High levels of ConA bound to the brush border of 
enterocytes from CD patients but not to that of enterocytes from 
controls (Figure 2D). These results demonstrate a high expression 
of mannosylated molecule(s) on the apical surface of the primary 
ileal enterocytes of CD patients.
Expression of carcinoembryonic antigen–related cell adhesion molecules 5 
and 6 is upregulated in CD ileal biopsies. Several glycosylated receptors 
for type 1 pili have been documented, such as glycosylphosphati-
dylinositol-anchored (GPI-anchored) protein CD48, Tamm-Hors-
fall protein (THP), and various family members of carcinoembry-
onic antigen–related cell adhesion molecules (CEACAMs) (16–20). 
Western blot analysis of total protein extract from ileal specimens 
of 9 CD patients, taken in both involved and uninvolved areas, and 
of 9 controls showed a strong expression of CEACAM5 (also called 
CEA or CD66e) and CEACAM6 (also called CD66c or non–cross-
reacting antigen [NCA]) in the ileal mucosa of CD patients in both 
involved and uninvolved areas (Figure 3A). No expression of THP, 
CD48, or CEACAM1 was found (data not shown). Blots of total 
cell lysates were probed with ConA-HRP to determine how many 
glycoproteins were upregulated or had increased mannose. The 
overall intensity of the signal was higher in ileal CD specimens 
compared with controls (data not shown). However, it was not 
possible to determine the number of glycoproteins upregulated in 
Figure 1
Adhesion of CD-associated AIEC strain LF82 to the brush border of 
ileal enterocytes. (A) Phase contrast microscopy of the adhesion of 
strain LF82 to the brush border of ileal enterocytes isolated from a CD 
patient and a control. Original magnification, ×1,000. (B) Indices of 
adhesion of AIEC strain LF82 to the brush border of ileal enterocytes 
isolated from 15 CD patients and 9 controls. The number of bacteria 
adherent to the brush border of 30–50 enterocytes was determined. 
Adhesion index was expressed as the mean number of bacteria adher-
ent to the brush border of 1 enterocyte. Two separate experiments 
were performed in duplicate.
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CD ileal specimens. A basal expression of CEACAM6 was observed 
in the colonic mucosa of the 3 control patients without IBD test-
ed (Figure 3B). No upregulation of CEACAM6 expression was 
observed in the colonic mucosa, in contrast to the ileal mucosa, 
of CD patients. We also observed that CEACAM6 expression was 
not elevated in the colon of UC patients (Figure 3B). These results 
indicate that the upregulation of CEACAM6 expression is specific 
to the ileal segment of the intestine of CD patients.
AIEC LF82 bacteria recognize CEACAM6 receptor on CD ileal entero-
cytes. Pretreatment of primary ileal enterocytes isolated from CD 
patients with an anti-CEACAM6 monoclonal antibody strongly 
decreased LF82 adhesion, whereas pretreatment with anti-CD48, 
-CEACAM1, -CEACAM5, or -THP monoclonal antibodies had no 
effect on LF82 adhesion (Figure 3C). LF82 adhesion inhibition using 
anti-CEACAM6 antibodies was observed with all 4 specimens from 
individual CD patients (Figure 3D). Confocal microscopy exami-
nation of HeLa cells transfected with cloned human CEACAM6 
cDNA showed that AIEC LF82 bacteria adhered preferentially 
to HeLa cells expressing a high level of CEACAM6 (Figure 3E). 
This adhesion could be blocked in the presence of d-mannose, 
and no adhesion was observed with the nonpiliated LF82 mutants 
(data not shown). Taken together, these data clearly demonstrate 
that adhesion of E. coli strain LF82 to the ileal mucosa of CD 
patients involves type 1 pili binding to the GPI-anchored receptor 
CEACAM6 expressed on the apical side of ileal epithelial cells.
CD patients express a high level of CEACAM6 molecules on the ileal 
epithelium. Immunohistochemical analysis was performed on the 
ileal and colonic mucosa of 20 CD patients and 20 controls using 
mouse anti-human CEACAM6 monoclonal antibody (clone 9A6). 
In CD patients, positive staining was observed on both uninvolved 
and involved ileal mucosa in 11 individuals and on inflamed 
mucosa alone in 6 others. In uninvolved mucosa of CD patients, a 
focal expression of CEACAM6 was observed on the apical surface 
of ileal epithelial cells with a marked gradient between villus and 
crypt epithelial cells (Figure 4A, top left). Examination of inflamed 
areas of ileal mucosa from patients expressing CEACAM6 on 
uninvolved mucosa revealed a stronger expression of CEACAM6 
on the apical surface and the cytoplasm of epithelial cells, as 
well as on the surface of goblet cells and infiltrating immune 
cells known to express CEACAM6 (21) (Figure 4A, middle left). 
In 2 patients undergoing surgery for ileal stenosis, we observed 
strong staining of the ileal epithelial cells together with staining 
of infiltrating immune cells (Figure 4A, bottom left). No staining 
was observed with the isotype-matched (IgG1) control (Figure 4A, 
right column). In 17 of the 20 controls tested, no staining of ileal 
epithelial cells was observed (Figure 4B, left), even in areas where 
infiltrating immune cells were present (Figure 4B, right). A focal 
expression of CEACAM6 similar to that shown in Figure 4A (top 
left) was observed with ileal specimens of 3 controls. Two had 
right colon cancer, and 1 had ileal ischemia of unknown etiology. 
Figure 2
Type 1 pili–mediated adhesion to the brush border of ileal enterocytes. (A) Adhesion of the LF82-derived type 1 pili–negative mutant 52D11 (fimA::
Tn5phoA) to the brush border of enterocytes isolated from CD patients and controls. (B) Adhesion of AIEC LF82 to the brush border of enterocytes 
isolated from CD patients and controls in the absence or presence of 2% d-mannose. (C) Adhesion of LF82 bacteria expressing type 1 pili variant 
and of nonpathogenic E. coli K-12 transformed with pPil38 to induce the expression of K-12 type 1 pili (left panel) or of LF82 bacteria expressing 
either LF82 type 1 pili variant or K-12 type 1 pili (middle panel) to the brush border of enterocytes isolated from CD patients. Western blot analysis 
using anti–type 1 pili antibodies performed on whole bacterial extracts showed similar amounts of type 1 pili expressed by the various strains 
(right panel). (D) Expression of a highly mannosylated molecule on the brush border of ileal enterocytes isolated from CD patients. Phase contrast 
microscopy and fluorescence labeling using ConA-FITC of ileal enterocytes from a CD patient and a control. Original magnification, ×400.
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Collectively, immunostaining examination revealed significantly 
increased expression of CEACAM6 in the uninvolved or inflamed 
ileal mucosa of CD patients compared with the mucosa of controls 
without IBD. The expression of CEACAM6 on the surface of ileal 
epithelium was absent in 85% of the controls without IBD, mod-
erate in 50% of CD patients and 15% of controls, and strong to 
very strong in 35% of CD patients (Figure 4C). Statistical analysis 
indicated that the prevalence of strong to very strong ileal expres-
sion of CEACAM6 was higher in patients with CD than in controls 
(P = 0.0007). Interestingly, significantly higher expression of 
CEACAM6 was also found in uninvolved ileal mucosa of CD 
patients compared with that of controls (P = 0.008). Analysis of 
colonic specimens showed that CEACAM6 was expressed on colon-
ic mucosa of all CD patients and controls. There was no marked 
difference in CEACAM6 expression between CD patients and con-
trols except in those with colorectal cancer (data not shown).
CEACAM6 expression is upregulated by proinflammatory cytokines 
and AIEC infection in intestinal epithelial cells. Of the various intesti-
nal epithelial cell lines used in this study, only Caco-2, LS174, and 
T84 expressed CEACAM6 (Figure 5A). However, no correlation 
was observed between the adhesion levels of AIEC strain LF82 
and the levels of CEACAM6 expression with the various cell lines 
tested (data not shown). The reason may be that the repertoire of 
glycoproteins abnormally expressed or abnormally glycosylated 
in all these undifferentiated cancer cell lines is very broad. When 
differentiated Caco-2 cells infected with strain LF82 bacteria 
were used, a clear colocalization between CEACAM6 expression 
and adherent bacteria was observed. This was confirmed by 3D 
reconstruction images showing apical expression of CEACAM6 
beneath adherent bacteria (Figure 5B).
IFN-γ or TNF-α stimulations, but not LF82 infection, weakly 
induced CEACAM5 in Caco-2 cells, whereas no CEACAM1 expres-
sion was observed (Figure 5C). IFN-γ strongly increased CEACAM6 
protein expression and, to a lesser extent, TNF-α also increased 
CEACAM6 expression. Interestingly, an increase in CEACAM6 
protein level was observed in Caco-2 cells after 3 hours of infec-
tion by AIEC strain LF82 at an MOI of 10 (Figure 5C). In addition, 
neither LF82 infection nor IFN-γ or TNF-α stimulation induced 
CEACAM6 expression on Colo205, SW480, and HCT-116 intes-
tinal epithelial cells in which no endogenous CEACAM6 protein 
was detected (data not shown). This indicates that inflamma-
tory conditions or infection with pathogenic bacteria can induce 
CEACAM6 expression only in intestinal epithelial cells express-
ing CEACAM6 at a basal level. Finally, the ability of AIEC strain 
LF82 to adhere to Caco-2 cells was significantly increased in a 
dose-dependent manner when the expression of CEACAM6 was 
induced after 1 and 2 days of IFN-γ stimulation (Figure 5D). In 
addition, this effect was reversed in the presence of CEACAM6 
siRNA, whereas control siRNA, which did not reduce CEACAM6 
protein levels, had no effect on AIEC LF82 adhesion (Figure 5D). 
Together, these findings demonstrate that the AIEC adhesion level 
increases with CEACAM6 expression by intestinal epithelial cells.
Discussion
We show that CD-associated AIEC strains adhere to the brush 
border of primary ileal enterocytes prepared from CD patients 
but not to enterocytes from controls without IBD. In normal 
human gut, commensal E. coli are not able to adhere to the apical 
face of intestinal epithelial cells. Only pathogenic E. coli, which 
have acquired, by horizontal transfer, virulence genes encoding 
adhesive factors have the ability to adhere to the apical surface 
of differentiated intestinal epithelial cells. For example, entero-
toxigenic E. coli (ETEC) synthesize specific adhesive factors called 
colonization factor antigens (CFAs) (22) that specifically bind 
asialoganglioside GM1 expressed on the brush border of small 
intestine enterocytes (23, 24). In a more specific manner, entero-
pathogenic E. coli (EPEC) or enterohemorrhagic E. coli (EHEC) use 
a type III secretion machinery to attach to intestinal epithelial 
cells, translocating their own receptor for intimate attachment 
(translocated intimin receptor [Tir]) into the host cell, which then 
binds to intimin on the bacterial surface (25, 26). Finally, Afa/Dr 
adhesins of diffusely adhering E. coli (DAEC) allow bacteria to 
bind to human decay-accelerating factor (DAF) or carcinoembry-
onic antigen molecules (27). We previously reported that AIEC 
strains do not possess any of the genes encoding known adhesive 
factors of pathogenic E. coli strains involved in either intestinal or 
extraintestinal infections but do express type 1 pili (9, 14). Type 1 
pili are common filamentous bacterial appendages, and the FimH 
adhesin located at the tip of the fibrillum structure can mediate 
bacterial adhesion to nonglycosylated host receptors, including 
the matrix-associated type I and IV collagens, laminin and fibro-
nectin, and to glycosylated receptors (28). Most AIEC strains asso-
Table 1
Ability of various AIEC strains and the corresponding fimH mutants to adhere to the brush border of primary ileal enterocytes isolated from 
CD patients
	 AIEC	strain
CD	patient	 Group	 LF82	 LF31	 LF71	 LF73	 LF100
1 WT 0.93 ± 0.24 1.08 ± 0.31 0.83 ± 0.03 0.88 ± 0.39 0.86 ± 0.38
 ΔfimH mutant 0.13 ± 0.11A 0.07 ± 0.04A 0.17 ± 0.03A 0.05 ± 0.07A 0.03 ± 0.03A
 +d-mannoseB 0.20 ± 0.07A 0.11 ± 0.03A 0.03 ± 0.04A 0.19 ± 0.06A 0.10 ± 0.05A
2 WT 1.07 ± 0.09 1.37 ± 0.52 0.75 ± 0.35 0.55 ± 0.14 0.83 ± 0.21
 ΔfimH mutant	 0.05 ± 0.07A	 0.07 ± 0.10A	 0.13 ± 0.03A	 0.35 ± 0.05	 0.08 ± 0.04A
 +d-mannoseB 0.18 ± 0.11A 0.30 ± 0.11A ND ND 0.25 ± 0.07
3 WT 1.22 ± 0.16 1.26 ± 0.30 0.77 ± 0.07 1.15 ± 0.38 1.01 ± 0.29
 ΔfimH mutant	 0.10 ± 0.10A	 0.11 ± 0.07A	 0.08 ± 0.04A	 0.35 ± 0.27	 0.18 ± 0.16A
 +d-mannoseB 0.22 ± 0.15A 0.25 ± 0.10A 0.23 ± 0.11 0.25 ± 0.14 0.28 ± 0.15
Values represent adhesion index. AP < 0.05. BAdhesion indices of wild-type strains in the presence of 2% d-mannose. ND, not determined.
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ciated with CD ileal mucosa express a type 1 pili variant (14), and 
interestingly we observed in the present study that expression of 
type 1 pili variant, compared with that of K-12 type 1 pili, enhanc-
es bacterial adhesion to the ileal enterocyte brush border. This 
could be a possible explanation of the high prevalence of AIEC 
associated with the ileal mucosa in CD patients (15).
AIEC adhesion to ileal enterocytes of CD patients was blocked 
in the presence of d-mannose, indicating that bacteria–host cell 
interactions occur via glycosylated receptors. In addition, an ele-
vated expression of mannosylated molecule(s) on ileal enterocytes 
of CD patients was observed using the mannose-binding lectin 
ConA. This could indicate the presence of: (a) a receptor differen-
tially expressed between CD patients and controls; or (b) truncat-
ed forms of oligosaccharide chains with mannose residues present 
in the terminal position owing to incomplete glycosylation. The 
latter hypothesis has been suggested by results in patients with 
UC (29–31). As we found that the adhesion of AIEC strains occurs 
via type 1 pili, we focused on the expression of known type 1 pili 
receptors by intestinal 
epithelial cells isolated 
from patients and 
controls. Among the 
glycosylated type 1 
pili receptors, such as 
GPI-anchored protein 
CD48, THP, and vari-
ous family members 
of CEACAM molecules 
(16–20), our findings 
show an upregulation 
of  CEACAM5 and 
CEACAM6 molecules 
i n  b o t h  i n v o l v e d 
a n d  u n i n v o l v e d 
ileal mucosa of CD 
patients.  Adhesion 
inhibi t ion  exper i -
ments in the presence 
of antibodies raised 
against the putative 
type 1 pili receptors 
indicated that AIEC 
strain LF82 binds to 
t h e  G P I - a n c h o r e d 
receptor CEACAM6 
expressed on the api-
cal side of epithelial 
cells of the ileal muco-
sa of CD patients. This 
result is intriguing, 
since CEACAM5 and 
CEACAM6 molecules 
are both highly man-
nosylated. A possible 
explanation could be 
that CEACAM5 is not 
accessible for type 1 
piliated bacteria when 
expressed in vivo by 
ileal epithelial cells.
Previous reports have evidenced a selectively enhanced expres-
sion of CEACAM6 but not of CEACAM5 in the serum of CD 
patients, indicating a stronger upregulation of the former mol-
ecule (32). These findings suggest that the high level of CEACAM6 
observed in CD patient sera could result from the overexpression 
of CEACAM6 by ileal epithelial cells. CEACAM6 is expressed by 
colonic epithelial cells and is upregulated in colorectal tumors 
(32–34), but we report here that CEACAM6 is not upregulated in 
the colonic mucosa of IBD patients. However, there is documented 
evidence that CEACAM6 is not expressed by epithelial cells of the 
small intestine in non-IBD patients (35) and that normal mucosa 
does not generally display ConA binding activity (36).
Overexpression of CEACAM6 by ileal epithelial cells in CD 
patients can be induced in at least 2 different ways, either by direct 
stimulation with pathogenic bacteria or by stimulation with pro-
inflammatory cytokines. The in vitro experiments reported here 
show that CEACAM6 expression in cultured intestinal epithelial 
cells is upregulated both by AIEC infection and by stimulation with 
Figure 3
CEACAM6 expression supports AIEC adhesion. (A) Western blot analysis of whole protein extracts from ileal biop-
sies taken in both involved and uninvolved areas of 9 CD patients and from 9 ileal biopsies from controls using anti-
CEACAM5, anti-CEACAM6, and anti–β-actin antibodies. (B) Western blot analysis of whole protein extracts from 
colonic biopsies from 3 controls, 3 UC patients, and 3 CD patients using anti-CEACAM6 and anti–β-actin antibodies. 
(C) Adhesion indices of AIEC strain LF82 to the brush border of enterocytes from CD patients in the presence of 
monoclonal antibodies raised against CEACAM1, CEACAM5, CEACAM6, THP, and CD48. (D) Adhesion indices of 
AIEC strain LF82 to the brush border of enterocytes from 4 CD patients in the presence of anti-CEACAM6 mono-
clonal antibody. (E) Confocal microscopic analysis of HeLa cells transfected with human CEACAM6 cDNA cloned 
and infected with AIEC LF82 harboring a GFP construct. Original magnification, ×1,000. CEACAM6 expression was 
detected using anti-CEACAM6 monoclonal antibody and a Texas red–conjugated anti-mouse IgG. Arrows show 
clear colocalization (yellow staining) between CEACAM6 and bacteria.
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the proinflammatory cytokines IFN-γ and TNF-α. Upregulation of 
CEACAM molecules by IFN-γ stimulation has been previously doc-
umented (37). The fact that TNF-α is also able to induce increased 
expression of CEACAM6 is of interest, since macrophages infected 
with AIEC bacteria secrete large amounts of TNF-α (13). Thus, 
AIEC bacteria can promote their own colonization in CD patients 
directly by inducing an increased expression of CEACAM6 by 
intestinal epithelial cells and indirectly via the induced secretion 
of TNF-α by infected macrophages. We believe this to be a novel 
example of a bacterial pathogen subverting functional membrane-
bound proteins as receptors for colonizing epithelia and exploit-
ing cell signaling pathways to cross-talk with the host cells. Like-
wise, Neisseria gonorrhoeae upregulates the opacity-associated (Opa) 
protein adhesion receptor CEACAM1 on primary endothelial cells 
(38); Afa/Dr DAEC infection induces increased neutrophil tran-
sepithelial migration, which in turn promotes cytokine-dependent 
upregulation of the Afa/Dr receptor CD55 (39); and adhesion of 
nontypeable Haemophilus influenzae upregulates the expression of 
its receptor, ICAM-1, by respiratory epithelial cells (40).
The issue of whether the upregulation of CEACAM6 expression 
in the ileal mucosa of CD patients is a primary or secondary con-
sequence of CD remains unclear. A basal expression of CEACAM6 
was observed in macroscopically uninvolved ileum in the majority 
of CD patients, which suggests that CEACAM6 expression is not 
merely a consequence of active inflammation. However, it could 
be due to sustained immune stimulation with increased levels of 
inflammatory cytokines even in the absence of patent inflamma-
tion, as already reported for the intestinal mucosa of CD patients 
(41). Alternatively, inducible expression of CEACAM6 in the ileal 
mucosa of CD patients could be genetically linked. We observed 
that cytokine stimulation of intestinal epithelial cells that did 
not express CEACAM6 did not induce CEACAM6 expression. 
The significantly increased ileal CEACAM6 expression found in 
uninvolved ileal mucosa of CD patients compared with controls 
without IBD could suggest that patients expressing a basal level of 
CEACAM6 are genetically predisposed to overexpression of that 
molecule. Of note, the gene encoding CEACAM6 is located on the 
long arm of human chromosome 19 (q13.2 between CYP2A and 
D19S15), close to a suggested IBD susceptibility locus (42).
Studies on the prevalence of AIEC strains in IBD patients and 
controls indicated that these pathogenic strains are isolated main-
ly from patients with CD and associated with ileal mucosa (36.4%) 
but rarely found in colonic mucosa (3.7%). AIEC strains are rarely 
associated with ileal or colonic mucosa of controls, or with colon-
ic mucosa of UC patients (15). We observed a basal expression of 
CEACAM6 in the colonic mucosa of CD and UC patients and con-
trols, which was consistent with findings of a previous report (35). 
Thus, a higher prevalence of AIEC in the colonic mucosa could 
have been expected. One possible explanation is that the concen-
tration of bacteria is higher in the colon than in the ileum, and 
therefore AIEC bacteria can be in competition with the normal 
flora to gain access to the CEACAM6 receptor.
In conclusion, our findings show that CEACAM6 acts as a host 
cell receptor for AIEC adhesion via a type 1 pili variant and suggest 
a causal role of CEACAM6 expression in colonization of the ileal 
mucosa of CD patients by AIEC strains. However, it remains to be 
determined whether CEACAM6 overexpression is due to the pres-
ence of AIEC or AIEC colonization is a consequence of CEACAM6 
upregulation. Hence, in addition to NOD2/CARD15, abnormal 
ileal CEACAM6 expression could be another susceptibility factor 
for CD. Accordingly, patients expressing a basal level of CEACAM6 
would be genetically predisposed to develop ileal CD, and the pres-
ence of AIEC bacteria and the secretion of IFN-γ and TNF-α would 
lead to an amplification loop of colonization and inflammation. 
We speculate that patients at high risk for developing severe ileal 
CD are those who, in addition to expressing a variant of the NOD2 
intracytoplasmic receptor (5, 6), overexpress CEACAM6 in the ileal 
mucosa. The new light thrown upon the etiology of ileal CD by our 
Figure 4
Tissue expression of CEACAM6. Immunohistochemistry staining of ileal sections from CD patients (A) and controls (B) using anti-CEACAM6 
monoclonal antibody clone 9A6 or isotype control. Original magnification, ×100. (C) Analysis of CEACAM6 expression in 20 CD patients and 20 
controls monitored from negative (–) to strongly positive (+++) staining as described in Methods.
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findings suggests that ileal CEACAM6 expression in IBD patients 
could be a diagnostic marker for ileal CD.
Methods
Patients. A total of 35 patients with ileal or ileocolonic CD and 29 con-
trols without IBD were included in this study. All patients and controls 
gave informed consent, and approval from Comité Consultatifs de Pro-
tection des Personnes dans la Recherche Biomédicale ([CCPPRB], Lille, 
France) was obtained. The diagnosis of CD was established using pre-
viously published criteria (43). The preparation of isolated ileal entero-
cytes was performed with resection specimens from 15 patients with CD 
(7 women, 8 men; mean age, 30 years; range, 17–52 years). Seven patients 
had undergone surgery for ileal involvement of CD and 8 for ileocolon-
ic CD. Enterocytes were also prepared from ileal surgery specimens or 
endoscopic biopsies from 9 controls without 
IBD (5 women, 4 men; mean age, 46 years; 
range, 16–70 years), of whom 3 had undergone 
right hemicolectomy for cancer.
The immunohistochemistry assays for 
CEACAM6 staining were performed on paraf-
fin-embedded ileal and colonic biopsies from 
20 CD patients (14 women, 6 men; mean age, 
38 years; range, 19–69 years). Eleven patients 
had only ileal involvement of CD, and 9 had 
ileocolonic CD. Analysis was also performed 
on ileal biopsies from 20 controls without 
IBD (14 women, 6 men; mean age, 58 years; 
range, 1 month–93 years), of whom 3 had 
indeterminate colitis with ileal inflammation 
and 4 had undergone right hemicolectomy for 
colonic cancer.
Western blot analysis of CEACAM6 expres-
sion by colonic specimens was performed 
on colonic biopsies from 3 CD patients 
(2 women, 1 man; mean age, 24 years; range, 
20–26 years), 3 UC patients (1 woman, 2 men; 
mean age, 47 years; range, 34–54 years), and 3 
controls (2 women, 1 man; mean age, 52 years; 
range, 37–62 years).
Bacterial strains, plasmids, and bacterial culture. 
E. coli strain LF82, isolated from a chronic ileal 
lesion of a CD patient, was used as the reference 
strain for AIEC, as well as 4 other AIEC strains, 
LF31, LF71, LF73, and LF100 (12). LF82 type 
1 pili–negative mutants harboring an insertion 
of the transposon Tn5phoA into fimA (52D11) 
or fimH (ZG2) gene were previously generated 
(14). AIEC-ΔfimH isogenic mutants were gen-
erated with a PCR product, using the method 
described by Datsenko and Wanner (44) and 
modified by Chaveroche et al. (45). The recom-
binant E. coli K-12 strain harboring pPil38 con-
taining the entire cloned fim operon was used 
for adhesion assays (46). Bacteria were grown 
routinely in Luria-Bertani (LB) broth or on LB 
or Mueller-Hinton agar plates (BD) overnight 
at 37°C without shaking.
In vitro adhesion to isolated enterocytes. In vitro 
adhesion assays were performed as previously 
described (22, 24). Isolated enterocytes were 
prepared from ileal specimens frozen at –80°C in MEM (Seromed Bio-
chrom) containing 10% glycerol and 10% DMSO (Sigma-Aldrich) imme-
diately after removal. Frozen intestinal samples were washed 3 times in 
PBS (pH 7.2), and the ileal mucosa was scraped with a coverslip to detach 
enterocytes. Approximately 105 isolated enterocytes were mixed with 108 
E. coli cells in MEM containing 10% of heat-inactivated FCS (Seromed 
Biochrom). After a 2-hour incubation period at 37°C with gentle shak-
ing, enterocytes were washed 3 times in PBS. Bacterial adhesion was 
quantified by examination under phase contrast microscopy at a magni-
fication of ×1,000. The number of E. coli bacteria adhering to the brush 
border of 30–50 enterocytes was counted in duplicate. Experiments with 
enterocytes were performed in duplicate by at least 2 different experi-
menters. The adhesion index was expressed as the mean number of bac-
teria attached to the brush border of 1 enterocyte.
Figure 5
CEACAM6 expression and LF82 adhesion ability with various intestinal epithelial cells. (A) 
Western blot analysis using monoclonal antibodies CEACAM6 clone 9A6 and anti–β-actin. Ten 
micrograms of total protein from different intestinal epithelial cell lines were loaded onto 4%–12% 
Tris-glycine gel. (B) Confocal microscopic analysis of differentiated Caco-2 cells infected with 
GFP-expressing LF82 bacteria. Original magnification, ×400. CEACAM6 was detected using 
anti-CEACAM6 monoclonal antibody clone 9A6 and a Texas red–conjugated anti-mouse IgG 
(top panel). Arrows show colocalization (yellow) between CEACAM6 and bacteria. A 3D recon-
struction (bottom panel) showed apical expression of CEACAM6 (red) and adherent bacteria 
(green). (C) Western blot analysis showing expression levels of CEACAM6, CEACAM5, and 
CEACAM1 by Caco-2 cells after 48 hours of stimulation with IFN-γ or TNF-α or after a 3-hour 
infection period with AIEC LF82 bacteria at an MOI of 10. As loading control, a labeling was 
performed using anti–β-actin polyclonal antibodies (D) Adhesion ability of AIEC LF82 bacteria 
was quantified after a 3-hour infection period at an MOI of 10 in Caco-2 intestinal epithelial cells 
after 1 and 2 days of IFN-γ stimulation. For RNA silencing, IFN-γ–stimulated Caco-2 cells were 
transfected with 10 ng of siRNA-blocking CEACAM6 (CEACAM6 siRNA) or 10 ng of nonworking 
siRNA (control siRNA). Expression of CEACAM6 was analyzed by Western blot analysis using 
anti-CEACAM6 monoclonal antibody clone 9A6 or anti–β-actin polyclonal antibodies. *P < 0.05 
compared with nonstimulated Caco-2 cells; #P < 0.05 compared with Caco-2 cells stimulated for 
2 days with IFN-γ and untransfected or transfected with control siRNA.
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Inhibition adhesion assays were performed either in the presence of 2% 
(wt/vol) d-mannose (Sigma-Aldrich) in MEM containing 10% FCS or after 
a 30-minute pretreatment of enterocytes at 37°C using various antibodies. 
Bacteria were then added, and adhesion assays were performed as described 
above. Monoclonal anti-CD48, anti-CEACAM1, anti-CEACAM5, and anti-
THP (PeliCluster; Tebu-Bio) and monoclonal anti-CEACAM6 clone 9A6 
antibodies were used at 1:100 dilution in MEM containing 10% FCS.
Analysis of the presence of free mannose residues on enterocyte brush border.  
Isolated enterocytes were incubated for 1 hour in PBS containing 50 μg/ml 
of ConA-FITC (Sigma-Aldrich) lectin, which specifically binds to mannose 
residues. After 4 washes, enterocytes were observed by fluorescence micros-
copy at a magnification of ×400.
Immunohistochemistry on ileal specimens. Immunohistochemistry was per-
formed on 4-μm sections of formalin-fixed paraffin-embedded tissue sam-
ples using the avidin-biotin peroxidase complex method and 3-amino,9-
ethyl-carbazole chromogen. Sections were subjected to heat-induced 
epitope retrieval using a pressure cooker for 3 minutes. Mouse anti-human 
CEACAM6 monoclonal antibody clone 9A6 was used at a 1:25 dilution. 
Sections were counterstained with Mayer’s hematoxylin. Analysis of quali-
tative staining was focused on the type of cell stained, the pattern of stain-
ing, and its distribution. CEACAM6 staining of individual tissue samples 
by monoclonal antibodies was compared and graded into 4 groups from 
negative (–) to strongly positive (+++): (–) indicates negative staining of 
cytoplasm and epithelial surface; (+) weakly positive staining of epithelial 
surface of scattered cells; (++) weakly to moderately positive staining of 
cytoplasm and epithelial surface of most cells; and (+++) strongly positive 
staining of cytoplasm and epithelial surface of most cells. For all the posi-
tively stained sections, adjacent sections were also stained with monoclonal 
mouse IgG1 (Sigma-Aldrich) as an isotype-matched control.
Cell culture, transfection, and in vitro adhesion assays. Caco-2, T84, HT29, 
HCT-116, Colo205, SW480, LS174, Int-407, and HeLa cells were obtained 
from ATCC and cultured as described previously (47). Two oligonucle-
otides, 19 residues in length (5ʹ-CCUCCUAAUAGUCAUACUA-3ʹ specific 
to the human CEACAM6 mRNA and 5ʹ-UUCUCCGAACGUGUCACGU-3ʹ 
as a control), were selected for synthesis of siRNA and transfected with a 
cationic lipid (Lipofectamine 2000; Invitrogen) according to the manufac-
turer’s instructions. The depletion of CEACAM6 expression by siRNA was 
confirmed by Western blot analysis. To determine the total number of cell-
associated bacteria corresponding to adherent and intracellular bacteria, 
Caco-2 cells were lysed after the 3-hour infection period, and the bacteria 
were quantified as previously described (14).
Protein extraction and immunoblotting experiments. Cells were seeded on 6-well 
plates and stimulated 24 hours later with 50 ng/ml of IFN-γ or TNF-α for 1 
or 2 days. Medium was removed and 300 μl of lysis buffer (1% Triton X-100, 
0.1 M NaCl, 10 mM HEPES pH 5.6, 2 mM EDTA, 4 mM Na3VO4, 40 mM NaF) 
supplemented with protease inhibitor cocktail (Complete Mini; Roche) was 
added. Lysates were harvested and passed 10 times through a 21G needle. 
The soluble protein fraction was obtained by centrifugation at 10,000 g for 
30 minutes at 4°C. Protein concentration was determined using the DC 
Protein Assay kit (Bio-Rad). Ten micrograms of proteins from all cells were 
separated on 4%–12% Tris-glycine gels (Invitrogen), blotted onto PVDF 
membranes, and stained using mouse anti-human CEACAM6 monoclonal 
antibody clone 9A6 for CEACAM6 and goat anti-human β-actin polyclonal 
antibody (C-11; Santa Cruz Biotechnology Inc.) for β-actin.
Expression of type 1 pili by bacteria was analyzed with whole-cell 
extracts. After an overnight incubation at 37°C in LB broth, bacteria at the 
same OD were centrifuged and resuspended in SDS-PAGE loading buf-
fer and heated for 5 minutes at 95°C. Protein preparations were acidified 
with HCl, heated for 5 minutes at 95°C, and separated by 12% SDS-PAGE. 
Western immunoblotting was performed using E. coli type 1 pili antibod-
ies (generous gift of Maryvonne Moulin-Schouleur, Pathogénie Bactéri-
enne, UR86, INRA, Nouzilly, France). Immunoreactants were detected 
using HRP–anti-rabbit IgG antibody (diluted 1:10,000), ECL reagents 
(Amersham), and autoradiography.
Confocal microscopy. HeLa cells, HeLa cells expressing human CEACAM6, 
and Caco-2 cells were seeded on sterile glass coverslips. After 24 hours for 
HeLa cells, or 15 days for Caco-2 cells, cells were infected for a 3-hour 
period with GFP-expressing LF82 bacteria (48) at an MOI of 10. Cells 
were stained using mouse anti-human CEACAM6 monoclonal antibody 
clone 9A6 and Texas red–conjugated anti-mouse IgG (Vector Laborato-
ries) as secondary antibody. Cells were observed with a Zeiss LSM 510 
Meta confocal microscope. A 3D reconstruction was performed using 
Velocity software (version 3.7.0).
Statistics. The χ2 test was used to compare adhesion to CD and control 
enterocytes and to analyze immunohistochemistry staining unless the vari-
ables required a 2-tailed Fisher’s exact test. A P value less than or equal to 
0.05 was considered statistically significant. For the analysis of significant 
differences of the other data, 1-tailed Student’s t test was used. A P value 
less than or equal to 0.05 was considered statistically significant.
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